VDR and familial pancreatic carcinoma: The VDR agonist paricalcitol is currently in phase I and II clinical trials in combination therapy with the chemotherapeutic agent gemcitabine to evaluate its safety and efficacy in treating pancreatic cancer (NCT03520790 (Perez, 2021) and NCT04617067 (Cancer Trials Ireland, 2021)) Table 1.